NDAORALTABLET
Approved
Apr 1957
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 15h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
MIRADON (anisindione) is an oral anticoagulant tablet approved in 1957 that belongs to the indanedione class of vitamin K antagonists. It is used to prevent thromboembolic complications in patients requiring anticoagulation, functioning through inhibition of vitamin K-dependent clotting factors. The drug represents an early-generation anticoagulant now facing obsolescence due to modern alternatives.
LOE Approaching
This legacy product faces imminent loss of exclusivity with minimal team resource allocation; positions are likely being consolidated or eliminated.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on MIRADON offers minimal career growth opportunity given its LOE-approaching lifecycle stage and zero linked job postings. This assignment is suitable only for professionals seeking stability in a maintenance role or gaining experience in legacy product management within a declining market.
Brand Manager (legacy)Regulatory Affairs Specialist
Worked on MIRADON at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.